Preliminary consultation on preferred product characteristics of benzathine penicillin G for secondary prophylaxis of rheumatic fever
Rosemary Wyber, Ben J Boyd, Samantha Colquhoun, Bart J Currie, Mark Engel, Joseph Kado, Ganesan Karthikeyan, Mark Sullivan, Anita Saxena, Meru Sheel, Andrew Steer, Joseph Mucumbitsi, Liesl Zuhlke, Jonathan Carapetis
DRUG DELIVERY AND TRANSLATIONAL RESEARCH | SPRINGER HEIDELBERG | Published : 2016
Rheumatic fever is caused by an abnormal immune reaction to group A streptococcal infection. Secondary prophylaxis with antibiotics is recommended for people after their initial episode of rheumatic fever to prevent recurrent group A streptococcal infections, recurrences of rheumatic fever and progression to rheumatic heart disease. This secondary prophylaxis must be maintained for at least a decade after the last episode of rheumatic fever. Benzathine penicillin G is the first line antibiotic for secondary prophylaxis, delivered intramuscularly every 2 to 4 weeks. However, adherence to recommended secondary prophylaxis regimens is a global challenge. This paper outlines a consultation with ..View full abstract
Funding from the Telethon New Children's Hospital Research Fund Supported this project. Formulation and drug development advice was kindly provided Medicines Development Limited and the Monash Institute of Pharmaceutical Sciences.